Last reviewed · How we verify
Ipilimumab and Fotemustine — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Ipilimumab and Fotemustine (Ipilimumab and Fotemustine) — Italian Network for Tumor Biotherapy.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Ipilimumab and Fotemustine TARGET | Ipilimumab and Fotemustine | Italian Network for Tumor Biotherapy | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Ipilimumab and Fotemustine CI watch — RSS
- Ipilimumab and Fotemustine CI watch — Atom
- Ipilimumab and Fotemustine CI watch — JSON
- Ipilimumab and Fotemustine alone — RSS
Cite this brief
Drug Landscape (2026). Ipilimumab and Fotemustine — Competitive Intelligence Brief. https://druglandscape.com/ci/ipilimumab-and-fotemustine. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing